Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)

被引：0
|
作者：
Solomon, B. [1 ]
Mersiades, A. [2 ]
Brown, C. [2 ]
Dawson, S. [1 ]
Wong, S. [1 ]
Tan, L. [3 ]
Yip, S. [2 ]
Cheung, Y. [2 ]
Jurkovic, H. [2 ]
Walker, M. [2 ]
Kao, S. [4 ]
Lee, C. K. [5 ]
Newnham, G. [6 ]
O'Byrne, K. [7 ]
Parakh, S. [8 ]
Jasas, K. [9 ]
Bray, V. [10 ]
Stockler, M. [2 ]
John, T. [3 ]
Pavlakis, N. [11 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia
[2] Univ Sydney, Nhmrc Clin Trials Ctr, Sydney, NSW, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[4] Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia
[5] St George Hosp, Dept Med Oncol, Sydney, ACT, Australia
[6] St Vincents Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[7] Princess Alexandra Hosp, Dept Med Oncol, Brisbane, Qld, Australia
[8] Austin Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[9] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA, Australia
[10] Liverpool Hosp, Dept Med Oncol, Sydney, NSW, Australia
[11] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR-mutated NSCLC; T790M resistance mutation; osimertinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.64
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 50 条
  • [41] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Kim, Youngwook
    Ko, Jeonghun
    Cui, Zhengyun
    Abolhoda, Amir
    Lee, Jeeyun
    Ahn, Jinseok
    Ou, Sai-Hong
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S421 - S421
  • [42] Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
    Sakai, Hitomi
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Hasegawa, Yoshikazu
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    ESMO OPEN, 2017, 2
  • [43] Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup Analysis
    Soria, Jean-Charles
    Kim, Sang-We
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Yang, Jin-Ji
    Ahn, Myung-Ju
    Wang, Jie
    Yang, James Chih-Hsin
    Lu, You
    Atagi, Shinji
    Ponce, Santiago
    Shi, Xiaojin
    Taylor, Rosemary
    Jiang, Haiyi
    Thress, Kenneth
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S207 - S208
  • [44] Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study
    Wang, Chin-Chou
    Lai, Chien-Hao
    Chang, Yu-Ping
    Chang, Huang-Chih
    Tseng, Chia-Cheng
    Huang, Kuo-Tung
    Lin, Meng-Chih
    THORACIC CANCER, 2021, 12 (23) : 3263 - 3272
  • [45] Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate)
    Mersiades, Antony
    Pavlakis, Nick
    Kao, Steven
    John, Tom
    Lee, Chee Khoon
    Dawson, Sarah-Jane
    Wong, Stephen
    Tan, Lavinia
    Yip, Sonia
    Brown, Chris
    Livingstone, Ann
    Cheung, Yvonne
    Jurkovic, Hannora
    Stockler, Martin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 199 - 200
  • [46] Emergence of CCDC6-RET Fusion with Maintained EGFR T790M Mutation After Resistance to Osimertinib in NSCLC: A Case Report
    Guo, Y.
    Guo, R.
    Cheng, H.
    Wang, H.
    Lou, F.
    Cao, S.
    Guo, W.
    Song, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S846 - S846
  • [47] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [48] Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
    Schmid, S.
    Klingbiel, D.
    Aeppli, S.
    Britschgi, C.
    Gautschi, O.
    Pless, M.
    Rothschild, S.
    Wannesson, L.
    Janthur, W.
    Foerbs, D.
    Demmer, I.
    Jochum, W.
    Fruth, M.
    LUNG CANCER, 2019, 130 : 149 - 155
  • [49] Non-invasive detection of EGFR T790M in gefitinib/erlotinib resistant NSCLC
    Kuang, Y.
    Rogers, A.
    Wang, L.
    Makrigiorgos, M.
    Vetrand, K.
    Thiede, S.
    Distel, R.
    Janne, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma
    Li, Dan
    Yang, DaFu
    Cui, SaiQiong
    Pan, Evenki
    Yang, Peng
    Dai, ZhaoXia
    ONCOTARGETS AND THERAPY, 2021, 14 : 4261 - 4265
12345